Waystar Weighs Sale Amid Market Challenges, Sources Reveal

Waystar, a prominent healthcare software provider, is reportedly exploring strategic options, including a potential sale. This move comes just two years after the company's initial public offering in New York. According to seven sources familiar with the situation, Waystar has engaged investment bank Evercore to guide the exploratory process, though discussions remain in preliminary stages.

Market Valuation Decline Spurs Strategic Review

The company, known for its technology that automates administrative tasks for hospitals and doctors, has seen its market value decrease to approximately $4.8 billion. This decline follows a 24% drop in its share price this year, attributed to a broader software sector selloff. The exploration of a sale could test the waters for renewed investor interest in software firms.

Waystar has strategically positioned itself as a technology entity, as opposed to a service-heavy healthcare business, to attract higher valuations. Initially, this approach resonated with investors, propelling its share price from $20 at the IPO to a peak of $45 in 2025. However, concerns about potential disruptions from artificial intelligence advancements have since pressured the stock, as noted by Morgan Stanley analysts in July.

Background and Ownership

Formed in 2017 from the merger of Zirmed and Navicure, Waystar went public in 2024 with backing from major stakeholders like EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT remains the largest shareholder with a 13% stake, followed by CPPIB at 10% and BlackRock Institutional Trust Company at 8%, according to LSEG data.

Despite the stock's recent struggles, Waystar's technology continues to play a critical role in the healthcare industry by streamlining payment processes. The company's decision to explore a sale reflects a broader trend of reevaluation among publicly traded software companies, as they navigate market volatility and technological advancements.

Responses and Future Prospects

While the possibility of a sale is being considered, sources caution that plans may change, and a transaction may not occur. Both Waystar and Evercore have declined to comment on the matter. Similarly, EQT, CPPIB, and BlackRock have not provided immediate responses to requests for comment.

The outcome of this strategic review could significantly impact Waystar's future direction and its role in the healthcare software market. As the company evaluates its options, stakeholders and industry observers will be closely watching for any developments that could influence its path forward.